Urology

There are stark differences in prostate cancer incidence and mortality rate among certain races, primarily between the African-Americans and their European-American counterparts. While the latter has mostly been attributed to lower socioeconomic positions; access to health care, racial and ethnic discrimination, language and cultural barriers and delayed disease diagnosis in these populations, the former has...

Minority patients are often at the nadir of society, being underrepresented in top economic reforms, and even in the medical research field. Recently, there has been rising evidence of the increasing disparities in risks, disease presentation and response to treatment among diverse ethnic groups. Hence the need to improve recruitment strategies to ensure maximum participation...

Black men are nearly 2.5 times more likely to be diagnosed with and die of prostate cancer compared to non-Hispanic white men.  A new study aims to debunk the long-held belief that this is due to genetic factors. JAMA Oncology’s research team led by the U-M Rogel Cancer Center analyzed data from more than 300,000...

Prostate Cancer Clinical Trial Update With Dr. Keith Crawford. Visit Prostate Health Education Network for more information on prostate cancer and clinical trials.

December 2019 Clinical Trials Update With Dr. Keith Crawford from the Prostate Health Education Network Visit http://www.prostatehealthed.org/phen_tv_video.php?tv_id=291 for monthly updates on clinical trials

The 2019 PHEN Summit was moderated by Dr. James Roberson and speakers included Brandon Mahal, MD and Daniel George, MD discussing the African American prostate cancer health disparity. Visit http://prostatehealthed.org/ for more from PHEN on prostate cancer and clinical trials.

On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with castration-resistant prostate cancer. Efficacy was investigated in ARCHES (NCT02677896), a trial enrolling 1150 patients with mCSPC randomized (1:1) to receive either enzalutamide orally 160 mg once...